tetano
Editor, Senior Moderator
Cureus
. 2022 Jan 30;14(1):e21740.
doi: 10.7759/cureus.21740. eCollection 2022 Jan.
COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports
Jia Hong Chen[SUP] 1 [/SUP], Ifeanyi A Ikwuanusi[SUP] 1 [/SUP], Veera Jayasree Latha Bommu[SUP] 1 [/SUP], Vraj Patel[SUP] 1 [/SUP], Harpreet Aujla[SUP] 2 [/SUP], Vishrut Kaushik[SUP] 1 [/SUP], Pramil Cheriyath[SUP] 1 [/SUP]
Affiliations
Abstract
After the surging rise in the Coronavirus disease 2019 (COVID-19) pandemic, the Food and Drug Administration (FDA) approved emergency approval of vaccinations to prevent life-threatening complications of COVID-19 infection. These vaccines are BNT162b2, mRNA-1273. Later, the FDA also approved JNJ-78436735. COVID-19 vaccination does not have major side effects, but there are some concerning adverse events reported right after vaccination. Myocarditis is one of them. Based on our analysis of 40 case reports, we are presenting the epidemiology and clinical picture of myocarditis related to the COVID-19 vaccine. Based on our analysis, we found that the majority of cases were seen in males with 90% predominance, and these cases were seen in the age group of 29.13 years old (mean, SD of 14.39 years). In 65% of cases, patients took the BNT162b2 vaccine; 30% of cases were reported with the mRNA-1273 vaccine; and 5% of cases with JNJ-78436735. Of all the cases, 80% of them are reported after the second dose of the vaccine with either Moderna or Pfizer. The characteristics of COVID-19 vaccine-related myocarditis were analyzed in this study. We identified several findings, ranging from age, gender, type of vaccination, presentation of symptoms, and diagnosis modality. This depicts the picture of COVID-19 vaccine-related myocarditis and what physicians should expect when dealing with the disease. Our analysis showed that more cases were reported after receiving the BNT162b2 vaccine compared to mRNA-1273 and JNJ-78436735 vaccines. Further research needs to be conducted to analyze the underlying cause of this association.
Keywords: and jnj-78436735 (johnson & johnson); bnt162b2 (pfizer-biontech); covid-19 vaccine; covid-19 vaccine related adverse events; janssen; mrna-1273 (moderna); myocarditis; pericarditis; vaccine related myocarditis.
. 2022 Jan 30;14(1):e21740.
doi: 10.7759/cureus.21740. eCollection 2022 Jan.
COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports
Jia Hong Chen[SUP] 1 [/SUP], Ifeanyi A Ikwuanusi[SUP] 1 [/SUP], Veera Jayasree Latha Bommu[SUP] 1 [/SUP], Vraj Patel[SUP] 1 [/SUP], Harpreet Aujla[SUP] 2 [/SUP], Vishrut Kaushik[SUP] 1 [/SUP], Pramil Cheriyath[SUP] 1 [/SUP]
Affiliations
- PMID: 35251812
- PMCID: PMC8887934
- DOI: 10.7759/cureus.21740
Abstract
After the surging rise in the Coronavirus disease 2019 (COVID-19) pandemic, the Food and Drug Administration (FDA) approved emergency approval of vaccinations to prevent life-threatening complications of COVID-19 infection. These vaccines are BNT162b2, mRNA-1273. Later, the FDA also approved JNJ-78436735. COVID-19 vaccination does not have major side effects, but there are some concerning adverse events reported right after vaccination. Myocarditis is one of them. Based on our analysis of 40 case reports, we are presenting the epidemiology and clinical picture of myocarditis related to the COVID-19 vaccine. Based on our analysis, we found that the majority of cases were seen in males with 90% predominance, and these cases were seen in the age group of 29.13 years old (mean, SD of 14.39 years). In 65% of cases, patients took the BNT162b2 vaccine; 30% of cases were reported with the mRNA-1273 vaccine; and 5% of cases with JNJ-78436735. Of all the cases, 80% of them are reported after the second dose of the vaccine with either Moderna or Pfizer. The characteristics of COVID-19 vaccine-related myocarditis were analyzed in this study. We identified several findings, ranging from age, gender, type of vaccination, presentation of symptoms, and diagnosis modality. This depicts the picture of COVID-19 vaccine-related myocarditis and what physicians should expect when dealing with the disease. Our analysis showed that more cases were reported after receiving the BNT162b2 vaccine compared to mRNA-1273 and JNJ-78436735 vaccines. Further research needs to be conducted to analyze the underlying cause of this association.
Keywords: and jnj-78436735 (johnson & johnson); bnt162b2 (pfizer-biontech); covid-19 vaccine; covid-19 vaccine related adverse events; janssen; mrna-1273 (moderna); myocarditis; pericarditis; vaccine related myocarditis.